Pharma & Biotech Daily: ACIP Updates, Stock Crashes, Rebranding, Layoffs & More

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The Advisory Committee on Immunization Practices (ACIP) has changed its recommendations for the MMRV vaccine for children under four, advising that the measles, mumps, rubella (MMR) vaccine be administered separately from the chickenpox vaccine. The committee is also expected to make changes to the childhood schedule for hepatitis B and COVID-19 vaccines. Replimune's stock has crashed after uncertainty surrounding the regulatory path for its tumor destroyer therapy, while a House bill has reignited hope for the FDA's rare pediatric priority review voucher program. Bluebird Bio has rebranded as Genetix Biotherapeutics following a private equity buyout, and Sino Biological has introduced a high-throughput platform for AI-driven antibody discovery. Several pharmaceutical companies have announced layoffs, impacting thousands of jobs.